All stock lists
Zura Bio Limited (NASDAQ:ZURA)
US · Delayed Price · Currency is USD
Also listed: 94E.FHealthcare · Biotechnology
0.96-3.13 (-76.55%)
Market cap
$92.4M
Insider Score
Health Score
Analyst consensus
Listed since
Mar 21, 2023
Website
Insider Score
––Not scored
ZURA Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
ZURA analyst forecast
ZURA analyst consensus
Moderate Buy2 ratings
Buy 2 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
ZURA 12-month price target
No published price targets in the last 12 months.
ZURA ratings mix, last 12 months
Buy Hold Sell
Best analysts covering ZURA
- Guggenheim100%success rate · +350.8% avg return · 1 call
- Oppenheimer60%success rate · +149.9% avg return · 5 calls
- Chardan Capital50%success rate · +140.6% avg return · 4 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
ZURA analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | Wedbush | Outperform | — | — | Reiterated | 2026-08-12 |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-08-12 |
| — | Wedbush | Outperform | — | — | Reiterated | 2026-07-01 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2026-03-23 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2026-03-20 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2025-11-14 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2025-09-30 |
| — | HC Wainwright & Co. | Neutral | — | — | Reiterated | 2025-08-19 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2025-08-15 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2025-08-15 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2025-05-09 |
| — | HC Wainwright & Co. | Neutral | — | — | Reiterated | 2025-04-03 |
| — | Guggenheim | Buy | — | — | Reiterated | 2025-03-26 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2025-03-26 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2025-03-26 |
| — | HC Wainwright & Co. | Neutral | — | — | Reiterated | 2024-12-24 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-12-11 |
| — | HC Wainwright & Co. | Neutral | — | — | Reiterated | 2024-11-18 |
| — | HC Wainwright & Co. | Neutral | — | — | Reiterated | 2024-11-11 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2024-11-08 |
| — | HC Wainwright & Co. | Neutral | — | — | Reiterated | 2024-10-21 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2024-09-19 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2024-05-10 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2024-04-01 |
| — | Raymond James | Strong Buy | — | — | Reiterated | 2023-08-15 |
ZURA earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-03-19 | -0.18 | -0.49 | $0 | $0 |
| 2026-05-07 | -0.17 | -0.22 | $0 | $0 |
| 2026-08-11 | -0.19 | -0.21 | $0 | $0 |
| 2026-10-27 | -0.20 | -0.20 | $0 | $0 |
| 2027-03-18Upcoming | -0.19 | — | $0 | — |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.